Background: Little is known about the epidemiology of cryptococcal meningitis in Taiwan. The aim of this study was to conduct the first nationwide population-based epidemiologic study of cryptococcal meningitis in Taiwan. Methods: Cases of cryptococcal meningitis were identified from the annual hospitalization discharge claims of the National Health Insurance Research Database with the corresponding ICD-9 code 321.0 from January 2000 to December 2007. Results: A total of 845 incident cases of cryptococcal meningitis were detected. Among them, 109 patients (12.9%) had human immunodeficiency virus (HIV) infection. The average incidence was 4.7 per million person-years. The incidence remarkably increased in the age group of 60–69 years, peaked in the age group of 70–79 years, and fell after the age of 80 years. The average incidence for men was 2.2-fold higher than that for women. The most common complication was obstructive hydrocephalus in 15.3% of the patients, followed by acute respiratory failure in 12.0% of the patients. Conclusion: This is the first population-based epidemiologic study of cryptococcal meningitis in Taiwan. The incidence was stable during the study period, and most cases were non-HIV related.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.